Table 2.
Number and proportion of patients with treatment discontinuations and treatment switches during 1, 2, 3, and 4 years of follow-up among those with the corresponding years of complete enrollment
| Year 1 (N = 319) |
Year 2 (N = 307) |
Year 3 (N = 266) |
Year 4 (N = 219) |
|||||
|---|---|---|---|---|---|---|---|---|
| Total number of discontinuationsa | n | % | n | % | n | % | n | % |
| 0 | 190 | 59.6 | 144 | 46.9 | 97 | 36.5 | 64 | 29.2 |
| 1 | 117 | 36.7 | 124 | 40.4 | 110 | 41.4 | 93 | 42.5 |
| 2 | 12 | 3.8 | 29 | 9.4 | 42 | 15.8 | 45 | 20.5 |
| 3 | 10 | 3.3 | 11 | 4.1 | 8 | 3.7 | ||
| 4 | 5 | 1.9 | 4 | 1.8 | ||||
| 5 | 1 | 0.4 | 4 | 1.8 | ||||
| 6 | 1 | 0.5 | ||||||
| Total number of switchesb | ||||||||
| 0 | 268 | 84.0 | 240 | 78.2 | 202 | 75.9 | 156 | 71.2 |
| 1 | 40 | 12.5 | 49 | 16.0 | 43 | 16.2 | 36 | 16.4 |
| 2 | 8 | 2.5 | 10 | 3.3 | 9 | 3.4 | 13 | 5.9 |
| 3 | 3 | 0.9 | 6 | 2.0 | 10 | 3.8 | 11 | 5.0 |
| 4 | 2 | 0.7 | 2 | 0.8 | 3 | 1.4 | ||
aDiscontinuations were defined as any gap in immunosuppressant prescriptions of > 6 months, or for rituximab any gap of > 1 year. Patients could be eligible for inclusion in both categories, since they could switch treatments before discontinuation; bswitch events were recorded based on prescriptions for alternative immunosuppressant regimens and included switches from monotherapy to combination and switches from combination to monotherapy with the same drug